Business
Spectral to present at Rodman & Renshaw Annual Global Investment Conference on September 10
-Company will also attend World Sepsis Day in New York on September 13- TORONTO, Sept. ...
About this update from Spectral Medical Inc
[{"type":"text","content":"\n\n\n\n\n\n-Company will also attend World Sepsis Day in New York on September 13-\n\n\nTORONTO, Sept. 4, 2012 /CNW/ - Spectral Diagnostics Inc. (TSX: SDI) (OTCQX: DIAGF), a Phase III company developing the first theranostic treatment for\n patients with septic shock, today announced that Dr. Paul Walker, the\n Company's President & Chief Executive Officer, is presenting at the\n Rodman & Renshaw 14th Annual Healthcare Conference. The conference is\n being held in New York City from September 9-11 at the Waldorf Astoria\n Hotel.\n\n\nDr. Walker will provide a corporate update and participate in a Q&A\n breakout session on Monday, September 10, 2012 at 3:40 PM ET in the\n Starlight Center room. Spectral's presentation will be available by\n webcast at:\n\n\nhttp://www.wsw.com/webcast/rrshq22/sdi.to\n\n\nFor additional information on the conference please visit:\n\n\nhttp://www.rodmanandrenshaw.com/conferences?id=176\n\n\nOn September 13, 2012, Spectral management will participate in the\n inaugural World Sepsis Day, in New York. The World Sepsis Day is an\n initiative of the Global Sepsis Alliance (GSA) and its founding\n members, all of which are non-profit organizations. The worldwide event\n is being held to raise the public and professional profile of sepsis -\n a problem that is common, global in scope, and devastating in its\n consequences, according to the GSA.\n\n\nAbout Spectral Diagnostics\nSpectral is a Phase III company seeking U.S. FDA approval for its lead\n theranostics product for the treatment of septic shock. Toraymyxin is a\n therapeutic hemoperfusion device that removes endotoxin, which can\n cause sepsis, from the bloodstream. Directed by the Company's Endotoxin\n Activity Assay (EAA™), the only FDA-cleared diagnostic for the risk of\n developing sepsis, Spectral's EUPHRATES trial is the world's first\n theranostics trial in the area of sepsis.\n\n\nToraymyxin has been approved for therapeutic use in Japan and Europe,\n and has been used safely and effectively in more than 100,000 patients\n to date. In March 2009, Spectral obtained the exclusive development and\n commercial rights in the U.S. for Toraymyxin, and in November 2010,\n signed an exclusive distribution agreement for this product in Canada.\n More than 250,000 patients are diagnosed with severe sepsis and septic\n shock in Nort...